Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.
Date
2019-12-18ICR Author
Author
Turkes, F
Carmichael, J
Cunningham, D
Starling, N
Type
Journal Article
Metadata
Show full item recordAbstract
Biliary tract cancers (BTCs) are poor prognosis malignancies with limited treatment options. Capecitabine has recently emerged as an effective agent in the adjuvant setting; however, treatment of advanced disease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global efforts in genomic profiling and molecular subtyping of BTCs have uncovered a wealth of genomic aberrations which may carry prognostic significance and/or predict response to treatment, and several targeted agents have shown promising results in clinical trials. As such, the uptake of comprehensive genomic profiling for patients with BTCs and the expansion of basket trials to include these patients are growing. This review describes the currently approved systemic therapies for BTCs and provides insight into the emerging targeted and immunotherapeutic agents, as well as conventional chemotherapeutic regimes, currently being investigated in clinical trials.
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
PHASE-II TRIAL
OPEN-LABEL
GEMCITABINE CHEMOTHERAPY
GROWTH-FACTOR
OXALIPLATIN
CISPLATIN
CHOLANGIOCARCINOMA
COMBINATION
GALLBLADDER
MULTICENTER
Research team
PrCa Targeted Therapy
Medicine (RMH)
Language
eng
Date accepted
2019-09-05
License start date
2019-12-18
Citation
Gastroenterology Research and Practice, 2019, 2019 pp. 7698786 -
Publisher
HINDAWI LTD